A Single-center Experience in Treating Young Children at High Risk For Severe COVID-19 With Sotrovimab

Pediatr Infect Dis J. 2022 Aug 1;41(8):e341-e342. doi: 10.1097/INF.0000000000003552. Epub 2022 Jul 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antibodies, Neutralizing
  • COVID-19 Drug Treatment*
  • Child
  • Child, Preschool
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • sotrovimab